Shire Recruiting 80-90 Fosrenol Reps; Adderall XR Adult User Fee Is Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Shire is recruiting 80 to 90 Fosrenol sales reps in anticipation of a second-half 2004 launch of the non-calcium phosphate binder for treatment of end-stage renal disease, the firm said April 29.
You may also be interested in...
Shire's non-calcium phosphate binding agent Fosrenol (lanthanum carbonate) is "approvable" Feb. 28 for treatment of end-stage renal disease patients undergoing hemodialysis. FDA is asking for additional data and analysis to address "a number of remaining questions," firm says. The agency previously requested a study examining long-term efficacy in bone histology (Pharmaceutical Approvals Monthly, Feb. 1, p. 3). Shire continues to forecast a U.S. launch prior to the end of 200
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011